Company Details
glenmark-pharmaceuticals
14,411
1,048,439
3254
glenmarkpharma.com
0
GLE_2962105
In-progress

Glenmark Pharmaceuticals Company CyberSecurity Posture
glenmarkpharma.comGlenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.
Company Details
glenmark-pharmaceuticals
14,411
1,048,439
3254
glenmarkpharma.com
0
GLE_2962105
In-progress
Between 750 and 799

Glenmark Pharmaceuticals Global Score (TPRM)XXXX



No incidents recorded for Glenmark Pharmaceuticals in 2025.
No incidents recorded for Glenmark Pharmaceuticals in 2025.
No incidents recorded for Glenmark Pharmaceuticals in 2025.
Glenmark Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating wit
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out mor
EMS is the leading pharmaceutical company in Brazil. Established since 45 years and with 100% national capital, the company has two industrial plants strategically placed in São Bernardo do Campo and Hortolândia, in the state of São Paulo. With a work based on daring, simplicity, excellence and res

We are Merck KGaA, Darmstadt, Germany and its global affiliates. We are a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to e

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important

As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portf
We are Sanofi, an innovative global healthcare company. We chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing t

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier li

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage
.png)
Dividend stocks this week: Major dividend stocks including Glenmark Pharma, Dixon Tech, and Mazagon Dock go ex-dividend this week—check the...
The UK arm of an international logistics giant returned to a pre-tax profit during its latest financial year after the prior period's...
Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after its unit signed a licensing deal with U.S....
India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have signed an exclusive...
Glenmark Pharmaceuticals is in talks with global drugmakers for a licensing deal on its ISB 2001 drug candidate being developed for use in the treatment of...
India's pharma sector has emerged as a big winner amid Trump's tariff woes, as the US has exempted pharmaceuticals from reciprocal tariffs,...
The event garnered deep insights into current trends, challenges, and opportunities, engaging over 175 senior delegates, industry leaders, and innovators.
The UK arm of an international logistics giant slipped to a pre-tax loss during its latest financial year after profits were impacted by a...
The divestment will involve 9609571 equity shares, to be executed through an offer for sale (OFS) on the stock exchange.

Explore insights on cybersecurity incidents, risk posture, and Rankiteo's assessments.
The official website of Glenmark Pharmaceuticals is http://www.glenmarkpharma.com.
According to Rankiteo, Glenmark Pharmaceuticals’s AI-generated cybersecurity score is 773, reflecting their Fair security posture.
According to Rankiteo, Glenmark Pharmaceuticals currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.
According to Rankiteo, Glenmark Pharmaceuticals is not certified under SOC 2 Type 1.
According to Rankiteo, Glenmark Pharmaceuticals does not hold a SOC 2 Type 2 certification.
According to Rankiteo, Glenmark Pharmaceuticals is not listed as GDPR compliant.
According to Rankiteo, Glenmark Pharmaceuticals does not currently maintain PCI DSS compliance.
According to Rankiteo, Glenmark Pharmaceuticals is not compliant with HIPAA regulations.
According to Rankiteo,Glenmark Pharmaceuticals is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.
Glenmark Pharmaceuticals operates primarily in the Pharmaceutical Manufacturing industry.
Glenmark Pharmaceuticals employs approximately 14,411 people worldwide.
Glenmark Pharmaceuticals presently has no subsidiaries across any sectors.
Glenmark Pharmaceuticals’s official LinkedIn profile has approximately 1,048,439 followers.
Glenmark Pharmaceuticals is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.
No, Glenmark Pharmaceuticals does not have a profile on Crunchbase.
Yes, Glenmark Pharmaceuticals maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/glenmark-pharmaceuticals.
As of December 11, 2025, Rankiteo reports that Glenmark Pharmaceuticals has not experienced any cybersecurity incidents.
Glenmark Pharmaceuticals has an estimated 5,376 peer or competitor companies worldwide.
Total Incidents: According to Rankiteo, Glenmark Pharmaceuticals has faced 0 incidents in the past.
Incident Types: The types of cybersecurity incidents that have occurred include .
.png)
FreePBX Endpoint Manager is a module for managing telephony endpoints in FreePBX systems. Versions prior to 16.0.96 and 17.0.1 through 17.0.9 have a weak default password. By default, this is a 6 digit numeric value which can be brute forced. (This is the app_password parameter). Depending on local configuration, this password could be the extension, voicemail, user manager, DPMA or EPM phone admin password. This issue is fixed in versions 16.0.96 and 17.0.10.
Neuron is a PHP framework for creating and orchestrating AI Agents. In versions 2.8.11 and below, the MySQLWriteTool executes arbitrary SQL provided by the caller using PDO::prepare() + execute() without semantic restrictions. This is consistent with the name (“write tool”), but in an LLM/agent context it becomes a high-risk capability: prompt injection or indirect prompt manipulation can cause execution of destructive queries such as DROP TABLE, TRUNCATE, DELETE, ALTER, or privilege-related statements (subject to DB permissions). Deployments that expose an agent with MySQLWriteTool enabled to untrusted input and/or run the tool with a DB user that has broad privileges are impacted. This issue is fixed in version 2.8.12.
Neuron is a PHP framework for creating and orchestrating AI Agents. Versions 2.8.11 and below use MySQLSelectTool, which is vulnerable to Read-Only Bypass. MySQLSelectTool is intended to be a read-only SQL tool (e.g., for LLM agent querying, however, validation based on the first keyword (e.g., SELECT) and a forbidden-keyword list does not block file-writing constructs such as INTO OUTFILE / INTO DUMPFILE. As a result, an attacker who can influence the tool input (e.g., via prompt injection through a public agent endpoint) may write arbitrary files to the DB server if the MySQL/MariaDB account has the FILE privilege and server configuration permits writes to a useful location (e.g., a web-accessible directory). This issue is fixed in version 2.8.12.
Okta Java Management SDK facilitates interactions with the Okta management API. In versions 11.0.0 through 20.0.0, race conditions may arise from concurrent requests using the ApiClient class. This could cause a status code or response header from one request’s response to influence another request’s response. This issue is fixed in version 20.0.1.
The Auth0 Next.js SDK is a library for implementing user authentication in Next.js applications. When using versions 4.11.0 through 4.11.2 and 4.12.0, simultaneous requests on the same client may result in improper lookups in the TokenRequestCache for the request results. This issue is fixed in versions 4.11.2 and 4.12.1.

Get company history
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Identify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.
Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.
Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.
Leverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.